Fault tolerant control for safe plant operation. November 10, 2016

Similar documents
Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics

Current FDA Perspective for Continuous Manufacturing

PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft)

Continuous Manufacturing: An Industry View

Scientific Considerations for Continuous API Manufacturing

How to Identify Critical Quality Attributes and Critical Process Parameters

Mitigating Commercial Risks in Continuous Manufacturing Drug Product

Regulatory Assessment

Continuous Manufacturing Achieving the Vision of Modernizing Pharmaceutical Manufacturing

Application of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013

Quality by Design for Drug Products. Dr. Lorenz Liesum Global Technical Operation, Novartis Swiss Association for Quality Meeting , Olten

BMS Experience with the FDA-EMA QbD/PAT Joint Pilot Ambarish K. Singh, PhD Director, Global Regulatory Sciences-CMC Bristol-Myers Squibb Company

Technology and Innovation are driving change in the pharmaceutical industry Stefan Krauß Business Segment Pharmaceuticals, Siemens AG

ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Annexes

Lifecycle Management of Process Analytical Technology Procedures

TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12

Siemens AG All rights reserved.

Roller Compaction: New trends, challenges and solutions

Strategic Implantation of PAT : FDA Perspective

Approaches to regulatory engagement and filing for continuous manufacturing

1. Master Batch Record Approvals Name Signature Date Originator

Association. Case Study 3. achieving real time release testing by a

Implementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork

Industry Perspective on Manufacturing in Early Development

Omron meets Pharma Milan, January 29 th Container Closure Integrity Testing (CCIT): a Risk Management Application

Managing Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA

Identifying and Controlling CPPs and CMAs

Scientific and Regulatory challenges in Quality by Design (QbD) submissions

QbD implementation in Generic Industry: Overview and Case-Study

MES Middle Ages Evolution Space. Florian Seitz Werum Asia Support Centre

Process Analytical Technology (PAT) / Quality by Design (QbD): Integrated Systems in the Future Pharma Business Landscape

A Case Study on the Possibilities of Industrial Internet in both PAT and Pharmaceutical Industry

Constrained Control and Optimization of Tubular Solid Oxide Fuel Cells for Extending Cell Lifetime

Scientific and Regulatory Considerations for Implementing Mathematical Models in the Quality by Design (QbD) Framework

Future of Pharmaceutical Quality and the Path to Get There

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

THE NEW QUALITY PARADIGM OPPORTUNITIES AND EXPECTATIONS IN ICH Q8 Q9 Q10 Q11 DR. FRITZ ERNI

ICH Q8/Q8(R)

Inspection. Implementation of ICH Q8, Q9, Q10

Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma

The Use of Stratified Sampling of Blend and Dosage Units to Demonstrate Adequacy of Mix for Powder Blends 1

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Maximizing Roller Compaction Benefits with Proper Excipient Selection

Three-tank System Exercise

Modeling and Control of a Multi-Component Continuous Crude Distillation Column Using LabVIEW

Dynamic Simulation and Control of MEA Absorption Process for CO 2 Capture from Power Plants

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

A Holistic Approach to Control and Optimisation of an Industrial Crushing Circuit

Modeling and Control of Coal Mill

Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology

Guidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.

The Emerging Technology Program: FDA s Perspective

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets

Thermo Scientific Twin-Screw Extruders Comprehensive Compounding and Extrusion Solutions for Materials Science

Successful Tableting Supplement. Continuous Tableting MODUL Q A-Type Tooling. engineering for a better world

Lifecycle Product Quality Risk Management

Process Control and Optimization Theory

On-line Parameter Estimation and Control for a Pilot Scale Distillation Column

Conducting Supplier Audits: Ensure Validation Compliance

NSF {Program (NSF ) first announced on August 20, 2004} Program Officers: Frederica Darema Helen Gill Brett Fleisch

Contents. Contents (13) 1 Production (23)

Digital Solutions for the Life Sciences Industry The connected product and manufacturing concept

Research Article. Quality by Design (QbD) Approach for Formulation Development of Hydralazine Hydrochloride Tablets

Novartis E2E CM case study

냉각결정화기술의응용전략 -2 고려대화공생명공학과양대륙

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

SENSOR NETWORK SERVICE INFRASTRUCTURE FOR REAL- TIME BUSINESS INTELLIGENCE

Evolution of Quality Assessments Recent Trends in FDA Queries. Mike Saleh, Pfizer Inc.

SupplementSeries PROCESS DESIGN I N T E R N A T I O N A L MARCH 2008 HARMONIZING THE CONCEPTS OF QBD, PAT, AND SYSTEMS BIOLOGY

!"#"$%& '%(%&)*+" !"#$%&&'$(')*#$+,$-(+./01& 2&$*(+/-#.$2)$1"#$,+33+42)* %5/2-6#)1$'--320'12+)$0'1#*+(2#& 7/1+6'12+)$').$ & ;'(1203#$:2<2)*

FLOTATION CONTROL & OPTIMISATION

MASTER PLANNING FOR VALIDATION

The long anticipated draft of the FDA s

STRATEGIES FOR CLEANING

Seamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson

A Power Plant Application

PI Control of a Continuous Bio-Reactor

Sliding Mode Control of a Bioreactor

MG2 and Valpharma: together for the improvement of the production process

FDA Quality Metrics Guidance

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary

GUIDELINE FOR THE STABILITY TESTING

Pelagia Research Library

Statistical Considerations for Review of Manufacturing Process

Application of Quality by Design in formulation and process Development

Thermal Modeling for Buildings. Karla Vega University of California, Berkeley Fall 2009

Using Predictive Modeling to Increase Efficiency and Effectiveness

Soft Constrained based MPC for Robust Control of a Cement Grinding Circuit

Meeting Solid Dose Formulation Challenges

GRAVIMAX Blenders & DOSIMAX Feeders

Full Length Original Research Paper

Successful Introduction of PAT Requires a Strategy

Quality Assessment & GMP Similarities & Differences

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Plantwide Control System Design

Real-time tablet API analysis: a comparison of a palm-size NIR spectrometer to HPLC method

Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Corn Analysis Modeling and Control

Transcription:

Real Time Release in Continuous Solid Dose Manufacturing: Systematic Characterization of Material Properties, and Optimal Design of Sensing and Control Methods Fault tolerant control for safe plant operation November 10, 2016

Content Introduction Systematic framework for control design & analysis Example: continuous feeder & blender system Summary & conclusions

Batch vs. continuous manufacturing [1] Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, Moore CMV, Yu LX, Woodcock J. Modernizing pharmaceutical manufacturing: from batch to continuous production. Journal of Pharmaceutical Innovation. 2015;10:191-199.

Continuous manufacturing in pharma. FDA Quality Related Guidance Initiatives e.g. PAT Guidance (2004)... e.g. OPQ Standup and ETT Formation (2015) Flexible demand Precise medicine Competiveness... Smaller production facilities Minimizing manufacturing cost Enhancing reliability and flexibility Monitoring & control drug quality on a continuous basis rather than through postproduction, batch-based testing

Continuous manufacturing pilot plant Potter B36 in Purdue University

Autonomous Portability Modularized design Operating conditions Process models Unit operations Process design Product design Material properties Demands for efficient process monitoring & control Implementation layer Final quality assurance Minimum Monitoring & control Challenges: Model-plant mismatch PAT calibration Process disturbance System interactions Process nonlinearity Plant start-up Plant shut-down Controllability Stability Robustness Self-adaptiveness Controller tuning

Content Introduction Systematic framework for control design & analysis Example: continuous feeder & blender system Summary & conclusions

Project objectives & outlines Operating cost Process maintenance Material database Process characterisation Feasible formulation space C4 System Performance & Verification Control variables Control set points C3 Process Monitoring & Control Process model C1 Material library C2 Sensing & RTR strategy Process parameters Unit operations Pilot plant

Systematic framework for control design & analysis (1) Layer 2 Use of dynamic models for prediction Model Predictive Control, Adaptive Control, Gain Scheduling, etc. Integrated across multiple unit operations R2 High Good Excellent Fail Layer 1 Based on PAT to measure CQAs and closed loop control (PFC) PID based more advanced control schemes Single or multiple unit operations R1 Medium Layer 0 Built-in control systems by manufacturers at unit operation level Simple PID control Single unit operation R0 Low T2P: Time to product M2P: Magnitude to product MRI: Morari s resilience index Hierarchical control architecture Risk levels & failure mode Evaluation & regulatory filling Sensor accuracy, precision, sampling time Sensor location Control architecture reconfiguration Control method Controller tuning [1] Morari M. Chem. Eng. Sci., 1983;38:1881-1891. Formulation optimization Process reconfiguration Continuous improvement e.g. Good Manufacturing Practices (GMP) guidelines Manufacturing processes are clearly defined and controlled. All critical processes are validated to ensure consistency and compliance with specifications. Manufacturing processes are controlled, and any changes to the process are evaluated. Changes that have an impact on the quality of the drug are validated as necessary.

Systematic framework for control design & analysis (2)

Hierarchical three-layer control MES: Manufacturing execution system SCADA: Supervisory control and data acquisition

L0 & L1 control design Mostly decentralized SISO PI/PID control loops Interactions among parallel control loops are important Interactions among hierarchical control loops 1. Selection of input/output variables Input and Output Effectiveness Controllability e.g., condition number (CN), relative gain array (RGA) Resilience e.g., Morari s Resilience Index (MRI) 2. Pairing and interaction analysis Pairing selection e.g. RGA, relative interaction array (RIA), Niederlinski Index (NI), singular value decomposition (SVD) Interaction e.g., Dynamic Interaction Measure (DIM) 3. Close-loop control system evaluation Stability e.g., Nyquist s stability criterion, Characteristic Loci Plots Robustness e.g., SVD, µ-based method Dynamic simulation e.g., MATLAB, Simulink [1] Asmar BN. Control of a two-stage refrigeration system. PhD Dissertation. University of Nottingham, 1999

L2 model-based control / real-time optimization Input U U(k+i) Process Output Y Measure Objective J Control algorithm U(k) Sensors Y(k+i) Model Y = f(x, u) Y(k) x: system state variables i = 1,2,..,Nc,...,Np Nc : control horizon Np: prediction horizon Model update State estimator Kalman filter Extended Kalman filter Unscented Kalman filter Moving horizon state estimator... f: state-space model data-based model empirical model First-principles model...

L2 MPC real-time implementation strategy Y(k) Y(k+1) K-1 k K+1 K+2 K+N C k+n P Past Current Future u(k t=k-1) u(k+1 t=k) U(k+1: k+np t=k) U(k: k+np-1 t=k-1) K-1 k K+1 K+2 K+N C k+n P Past Current Future MPC U(k+1: k+np t=k) Computation time sampling time

Risk analysis and control evaluation

Content Introduction Systematic framework for control design & analysis Example: continuous feeder & blender system Summary

Continuous dry granulation process Loss-inweight Feeders Continuous Blender Roller Compactor Mill Lube Continuous Blender Tablet Press

Feeder & blender control system Unit operation Process output (y) Process input (u) Control Layer Controller type API feeder API flowrate Screw rotation speed L0 PID Exp. feeder Exp. flowrate Screw rotation speed L0 PID API composition API flowrate L1/2 PID, Ratio, MPC Blender Powder flowrate Excipient flowrate L1/2 PID, MPC API mixing RSD Rotation speed L1/2 PID, MPC Rotation speed Motor current L0 PID

System identification: state-space models Continuous-time identified state-space model dx dt = A cx t + B c U(t) Y t = C c X t + D c U t + e(t) G = C 1 SI A B + D Discrete-time identified state-space model X k + 1 = A d X k + B d U(k) Y k = C d X k + D d U k + e(k) min du J = Y sp Y 2 + w u U 2 e k = w e e k 1 + 1 w e e(k) L1 control design decoupled control design e.g., condition number Niederlinski index relative gain array Morari s resilience index... L2 control design Linear MPC design Sampling time: 4s Kalman filter design State estimation...

System identification: training data Best fit *Sampling time of 4 second for all measurements, only 4 measurements shown here

System identification: validation data *Sampling time of 4 sec for all measurements

L1 control design & analysis: a check list Step one Step two Step three

L1 control for feeder & blender system L0-FC-1: PID FT FT L0-FC-2: PID API feeder MV:Exc. flowrate Excipient feeder L1-FC-1: PID L1-RC-1: Ratio SP: Blend flowrate L1-CC-2: PID MV:API mean comp & RSD. SP:API comp. SP: API RSD L1-RSD-1: PID L0-MC-1: N./A. FT MW /NIR Control architecture SP: Set point MV: Measured variable FT: Flowrate transducer CC: Composition control FC: Flowrate control RSD: Relative standard deviation Continuous blender RC: Ratio control MC: Motor control L0: Level 0 equipment control L1: Level 1 supervisory control MW/NIR: Microwave/near infrared

L0/2 control for feeder & blender system L0-FC-1: PID FT FT L0-FC-2: PID API feeder Excipient feeder SP:API comp. SP: RSD SP: powder flowrate L2 MPC MV:API mean comp. & RSD MV: Blend flowrate L0-MC-1: N./A. FT MW /NIR Control architecture SP: Set point MV: Measured variable FT: Flowrate transducer CC: Composition control FC: Flowrate control RSD: Relative standard deviation SP: Blender RPM Continuous blender MPC: Model predictive control MC: Motor control L0: Level 0 equipment control L1: Level 1 supervisory control MW/NIR: Microwave/near infrared

Feeder & blender simulation in Simulink/MATLAB Sampling time: FT: 1.0 s NIR: 2.0 s L0/1: real time L2 MPC: 4.0 s

R0 risk: mass flow disturbances due to feeder reloading R1 risk: calibration errors in the feeders Risk Analysis for feeder & blender: R0 & R1 L0 L1 L2

Risk Analysis for feeder & blender: R2 L1 L2 R2 risk: material flowability changed due to humility while a step change on the powder flow rate was also executed.

Risk Analysis summary Performance evaluation based on the API composition. + Indicators based on API mean composition; * Indicators based on API mixing RSD. Control D2R (s) M2P (%) R0 R1 R2 R0 R1 R2 Remark L0 176 + Fail Fail 0.65 + Fail Fail Fail for R1 & R2 L1 97 + 238 + 494* 0.38 + 1.52 + 0.48* Long D2R for R2 L2 81 + 183 + 259* 0.65 + 2.30 + 0.46* High M2P for R1 * Blender D2P: Duration to reject, s; M2P: Magnitude to product, %

Risk Analysis for feeder & blender: R2 PAT gross error Layer 0 control: no feedback control based on the PAT tools. Drift Drift The PAT tool of NIR for API composition measurement drifted from 40 to 100 seconds and suffered the gross error from 100 to 240 seconds before it was corrected.

Layer 1 control: The PAT tool with gross error detoured the API mean composition and its mixing uniformity from their set points. Drift Drift

Layer 2 control: The Kalman filter with data reconciliation can reject the measurement gross error when large model-plant mismatches detected. Drift Drift The Kalman filter with data reconciliation x k k = x k k 1 + M y k y k k 1 R = diag exp( e i cσ i 2 R

Summary & conclusions The primitive systematic framework for control design and analysis based on SIMULINK platform has been developed. L0 control loops response fastest to measurable R0 disturbances but fail to response to the unmeasurable disturbance R1. L1/2 control loops are capable of intermediate product quality control. L2 control based on MPC is beneficial but the maintenance cost is also high.